Skip to main content
. 2018 Sep 29;10(10):365. doi: 10.3390/cancers10100365

Figure 5.

Figure 5

Viability of naïve SKOV-3 cells treated with different combinations of target drugs: (AC) Sunitinib, Everolimus, or Temsirolimus, respectively, in combination with Notch inhibitor FLI-06 or alone; (D) Pazopanib in combination with mTOR inhibitor Temsirolimus; (E,F) Sorafenib or Sunitinib, respectively, in combination with Akt inhibitor Afuresertib or alone. Dashed line corresponds to single drug, solid line—combination.